세계의 치료 저항성 우울증 시장 보고서(2025년)

Treatment-Resistant Depression Global Market Report 2025

US $ 4,490 ￦ 6,170,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,918,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,666,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

치료 저항성 우울증 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 6.9%의 CAGR로 24억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 만성질환의 증가, 불안 장애의 유병률 증가, 정신건강 문제에 대한 인식 증가, 정부의 노력 강화, 의료 지출 증가 등의 요인에 기인할 것으로 보입니다. 예측 기간 동안 예상되는 주요 동향으로는 원격의료 및 디지털 헬스 확대, 진단 및 치료 기술의 발전, 정신건강에 대한 편견 감소 및 인식 개선 노력, 맞춤형 의료의 도입, 정신건강 치료에 인공지능의 통합 등이 있습니다.

정신장애의 유병률 증가는 치료 저항성 우울증(TRD) 시장의 성장을 촉진할 것으로 예상됩니다. 정신장애는 개인의 인지, 정서, 행동 기능에 영향을 미치는 다양한 상태를 포함하며, 많은 경우 일상 생활에 심각한 고통과 장애를 초래합니다. 이러한 질환의 높은 유병률은 유전적 소인과 같은 요인에 영향을 받습니다. 유전적 돌연변이는 뇌 화학을 변화시켜 우울증, 불안증, 정신분열증과 같은 질병에 대한 감수성을 증가시키기 때문에 TRD는 표준 치료가 효과가 없을 때 보다 개인화된 고급 치료 옵션을 제공함으로써 환자를 지원하고 회복 가능성과 전반적인 삶의 질을 향상시킬 수 있습니다. 예를 들어, 2023년 11월 미국심리학회(APA)는 18-34세 성인의 50%가 정신질환을 경험했으며, 이는 연령대 중 가장 높은 비율로 나타났다고 보고했습니다. 이러한 정신질환의 증가가 치료 저항성 우울증 시장의 성장에 기여하고 있습니다.

치료 저항성 우울증 시장의 주요 기업들은 환자의 미충족 수요를 충족시키고, 효능을 개선하며, 부작용을 최소화하기 위해 단제 요법과 같은 혁신적인 치료법 개발에 주력하고 있습니다. 단일요법은 여러 가지 치료법을 병용하는 것이 아니라 단일 치료법이나 약물을 사용하는 것으로, 치료 저항성 우울증 치료에 보다 집중적인 접근법을 제공합니다. 이 전략은 여러 약물에 반응하지 않는 환자에게 특히 유용합니다. 예를 들어, 2025년 1월 미국 제약 및 의료 기술 기업 존슨앤드존슨 서비스(Johnson & Johnson Services)는 SPRAVATO(에스케타민) 비강 스프레이가 미국 식품의약국(FDA)의 승인을 받아 성인의 치료 저항성 우울증에 대한 즉각적인 치료제로 승인되었다고 발표했습니다. SPRAVATO는 환자가 적어도 두 가지 이상의 다른 항우울제로 충분한 효과를 얻지 못한 경우 경구용 항우울제와 병용하여 사용됩니다. 이 약물의 빠른 효과는 효과가 나타나기까지 몇 주가 걸리는 기존 항우울제의 한계를 극복할 수 있습니다. 케타민의 유도체인 에스케타민은 뇌의 NMDA 수용체를 표적으로 작용하여 몇 시간 내에 기분을 개선할 수 있습니다. 이번 승인은 정신건강 치료에 있어 큰 진전입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 치료 저항성 우울증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 치료 저항성 우울증 시장 : 성장률 분석
• 세계의 치료 저항성 우울증 시장 실적 : 규모와 성장, 2019-2024
• 세계의 치료 저항성 우울증 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 치료 저항성 우울증 전체 시장(TAM)

제6장 시장 세분화

• 세계의 치료 저항성 우울증 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 선택적 세로토닌 재흡수 억제제(SSRIS)
• 모노아민 산화효소 억제제
• 삼환계 항우울제
• 사이케데릭스
• 기타 약물 클래스
• 세계의 치료 저항성 우울증 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 비경구
• 기타 투여 경로
• 세계의 치료 저항성 우울증 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 치료 저항성 우울증 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 홈케어
• 전문 클리닉
• 기타 최종사용자
• 세계의 치료 저항성 우울증 시장 선택적 세로토닌 재흡수 억제제(SSRIS) 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 플루옥세틴
• 세르트랄린
• 파록세틴
• 시탈로프람
• 에스시탈로프람
• 세계의 치료 저항성 우울증 시장 모노아민 산화효소 억제제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 페넬진
• 트라닐시프로민
• 이소카복사지드
• 셀레길린
• 세계의 치료 저항성 우울증 시장 삼환계 항우울제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 아미트립틸린
• 노르트립틸린
• 이미프라민
• 클로미프라민
• 독세핀
• 세계의 치료 저항성 우울증 시장, 환각제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 케타민
• 에스케타민
• 실로시빈
• 리세르산 디에틸아미드(LSD)
• 3,4-메틸렌디옥시메탐페타민(MDMA)
• 기타 약물 클래스
• 세계의 치료 저항성 우울증 시장, 기타 약물 클래스 유형별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세로토닌·노르에피네프린 재흡수 억제제(SNRI)
• 노르에피네프린·도파민 재흡수 억제제(NDRI)
• 글루탐산 모듈레이터
• 호르몬요법

제7장 지역별·국가별 분석

• 세계의 치료 저항성 우울증 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 치료 저항성 우울증 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 치료 저항성 우울증 시장 : 경쟁 구도
• 치료 저항성 우울증 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline(GSK) plc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Hikma Pharmaceuticals plc
• Neurocrine Biosciences Inc.
• Relmada Therapeutics Inc.
• Neuronetics Inc.
• COMPASS Pathways
• Lykos Therapeutics
• Reviva Pharmaceuticals
• Celon Pharma SA
• BrainsWay Ltd.
• Magstim Company Limited
• MindMed
• Alto Neuroscience
• Sage Therapeutics Inc.
• MindBio Therapeutics Ltd.
• Reunion Neuroscience

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 치료 저항성 우울증 시장 2029 : 새로운 기회를 제공하는 국가
• 치료 저항성 우울증 시장 2029 : 새로운 기회를 제공하는 부문
• 치료 저항성 우울증 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Treatment-resistant depression (TRD) is a severe and persistent form of major depressive disorder (MDD) that is characterized by an inadequate response to at least two different antidepressant treatments, each given at an adequate dose and duration. This condition leads to prolonged psychological distress and functional impairment. Individuals with TRD often require advanced therapeutic approaches, including novel pharmacological treatments, neuromodulation techniques, and personalized mental health interventions, to achieve symptom relief and improve overall well-being.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main drug classes used in the treatment of treatment-resistant depression include selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, tricyclic antidepressants, psychedelics, and others. SSRIs are a class of antidepressants that work by increasing serotonin levels in the brain, inhibiting its reabsorption into neurons, which enhances mood regulation and helps treat conditions such as depression and anxiety disorders. These medications are administered through various routes, including oral, parenteral, and others, and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Key end users include hospitals, homecare settings, specialty clinics, and other healthcare providers.

The treatment-resistant depression market research report is one of a series of new reports from The Business Research Company that provides treatment-resistant depression market statistics, including treatment-resistant depression industry global market size, regional shares, competitors with a treatment-resistant depression market share, detailed treatment-resistant depression market segments, market trends and opportunities, and any further data you may need to thrive in the treatment-resistant depression industry. This treatment-resistant depression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The treatment-resistant depression market size has grown strongly in recent years. It will grow from$1.76 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to several factors, including the rising cases of treatment-resistant depression, the increasing incidence of depression, improved access to healthcare facilities, growing awareness of available treatment options, and the high prevalence of mental health disorders.

The treatment-resistant depression market size is expected to see strong growth in the next few years. It will grow to$2.46 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth during the forecast period can be attributed to factors such as the rise in chronic diseases, the increasing prevalence of anxiety disorders, growing awareness of mental health issues, enhanced government initiatives, and higher healthcare expenditure. Key trends expected in the forecast period include the expansion of telemedicine and digital health, advancements in diagnostic and therapeutic technologies, efforts to reduce mental health stigma and raise awareness, the adoption of personalized medicine, and the integration of artificial intelligence in mental health treatment.

The increasing prevalence of mental disorders is expected to drive the growth of the treatment-resistant depression (TRD) market. Mental disorders encompass a wide range of conditions that affect an individual's cognitive, emotional, and behavioral functions, often resulting in significant distress and impairment in daily life. The high prevalence of these disorders is influenced by factors such as genetic predisposition, as inherited genetic variations can alter brain chemistry and increase the susceptibility to conditions such as depression, anxiety, and schizophrenia. TRD provides support for patients by offering more personalized and advanced treatment options when standard therapies fail, thereby improving their chances of recovery and overall quality of life. For example, in November 2023, the American Psychological Association (APA) reported that 50% of adults aged 18 to 34 experienced mental illnesses, the highest rate among age groups, while adults aged 35 to 44 saw the largest increase in diagnoses, with 45% reporting a mental illness. This rise in mental health conditions is contributing to the growth of the treatment-resistant depression market.

Leading companies in the treatment-resistant depression market are focused on developing innovative therapies, such as monotherapy, to address unmet patient needs, improve efficacy, and minimize side effects. Monotherapy involves the use of a single treatment or medication, as opposed to combining multiple therapies, offering a more focused approach to treating treatment-resistant depression. This strategy is particularly beneficial for patients who have not responded to several medications. For example, in January 2025, Johnson & Johnson Services Inc., a US-based pharmaceutical and medical technology company, announced the approval of SPRAVATO (esketamine) nasal spray by the U.S. Food and Drug Administration (FDA) as a fast-acting treatment for adults with treatment-resistant depression. SPRAVATO is used in conjunction with an oral antidepressant when patients have not adequately responded to at least two other antidepressants. The drug's rapid effects address the limitations of traditional antidepressants, which often take weeks to show results. As a derivative of ketamine, esketamine works by targeting the brain's NMDA receptors, potentially improving mood within hours. This approval represents a significant advancement in mental health treatment.

In October 2024, Resilience Lab, a US-based healthcare company, acquired Options MD for an undisclosed amount. This acquisition allows Resilience Lab to enhance its mental health services by integrating Options MD's specialized platform for treating severe and treatment-resistant depression. This move aims to expand access to personalized, evidence-based care. Options MD is a US-based telepsychiatry company specializing in the treatment of severe and treatment-resistant depression, bipolar disorder, post-traumatic stress disorder (PTSD), and other mental health conditions.

Major players in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, GlaxoSmithKline (GSK) plc., Hikma Pharmaceuticals plc, Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, Lykos Therapeutics, Reviva Pharmaceuticals, Celon Pharma SA, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience.

North America was the largest region in the treatment-resistant depression market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in treatment-resistant depression report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the treatment-resistant depression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The treatment-resistant depression market consists of revenues earned by entities by providing services such as psychiatric counseling, cognitive behavioral therapy (CBT), transcranial magnetic stimulation (TMS) therapy, electroconvulsive therapy (ECT), and ketamine infusion therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The treatment-resistant depression market includes sales of products such as esketamine nasal spray, vagus nerve stimulation (VNS) devices, deep brain stimulation (DBS) systems, neuromodulation devices, glutamate receptor modulators, and digital therapeutics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Treatment-Resistant Depression Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on treatment-resistant depression market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for treatment-resistant depression ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The treatment-resistant depression market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIS); Monoamine Oxidase Inhibitors; Tricyclic Antidepressant; Psychedelics; Other Drug Classes
• 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine; Sertraline; Paroxetine; Citalopram; Escitalopram
• 2) Monoamine Oxidase Inhibitors (MAOIs): Phenelzine; Tranylcypromine; Isocarboxazid; Selegiline
• 3) Tricyclic Antidepressants (TCAs): Amitriptyline; Nortriptyline; Imipramine; Clomipramine; Doxepin
• 4) Psychedelics: Ketamine; Esketamine; Psilocybin; Lysergic Acid Diethylamide (LSD); 3,4-Methylenedioxymethamphetamine (MDMA); Other Drug Classes
• 5) Atypical Antipsychotics: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs); Glutamate Modulators; Hormonal Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Abbott Laboratories; Novartis AG; GlaxoSmithKline (GSK) plc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Treatment-Resistant Depression Market Characteristics

3. Treatment-Resistant Depression Market Trends And Strategies

4. Treatment-Resistant Depression Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Treatment-Resistant Depression Growth Analysis And Strategic Analysis Framework

• 5.1. Global Treatment-Resistant Depression PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Treatment-Resistant Depression Market Growth Rate Analysis
• 5.4. Global Treatment-Resistant Depression Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Treatment-Resistant Depression Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Treatment-Resistant Depression Total Addressable Market (TAM)

6. Treatment-Resistant Depression Market Segmentation

• 6.1. Global Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitors (SSRIS)
• Monoamine Oxidase Inhibitors
• Tricyclic Antidepressant
• Psychedelics
• Other Drug Classes
• 6.2. Global Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.3. Global Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Treatment-Resistant Depression Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.5. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Selective Serotonin Reuptake Inhibitors (SSRIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluoxetine
• Sertraline
• Paroxetine
• Citalopram
• Escitalopram
• 6.6. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Monoamine Oxidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phenelzine
• Tranylcypromine
• Isocarboxazid
• Selegiline
• 6.7. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Tricyclic Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amitriptyline
• Nortriptyline
• Imipramine
• Clomipramine
• Doxepin
• 6.8. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Psychedelics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ketamine
• Esketamine
• Psilocybin
• Lysergic Acid Diethylamide (LSD)
• 3,4-Methylenedioxymethamphetamine (MDMA)
• Other Drug Classes
• 6.9. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
• Glutamate Modulators
• Hormonal Therapies

7. Treatment-Resistant Depression Market Regional And Country Analysis

• 7.1. Global Treatment-Resistant Depression Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Treatment-Resistant Depression Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Treatment-Resistant Depression Market

• 8.1. Asia-Pacific Treatment-Resistant Depression Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Treatment-Resistant Depression Market

• 9.1. China Treatment-Resistant Depression Market Overview
• 9.2. China Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Treatment-Resistant Depression Market

• 10.1. India Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Treatment-Resistant Depression Market

• 11.1. Japan Treatment-Resistant Depression Market Overview
• 11.2. Japan Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Treatment-Resistant Depression Market

• 12.1. Australia Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Treatment-Resistant Depression Market

• 13.1. Indonesia Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Treatment-Resistant Depression Market

• 14.1. South Korea Treatment-Resistant Depression Market Overview
• 14.2. South Korea Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Treatment-Resistant Depression Market

• 15.1. Western Europe Treatment-Resistant Depression Market Overview
• 15.2. Western Europe Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Treatment-Resistant Depression Market

• 16.1. UK Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Treatment-Resistant Depression Market

• 17.1. Germany Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Treatment-Resistant Depression Market

• 18.1. France Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Treatment-Resistant Depression Market

• 19.1. Italy Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Treatment-Resistant Depression Market

• 20.1. Spain Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Treatment-Resistant Depression Market

• 21.1. Eastern Europe Treatment-Resistant Depression Market Overview
• 21.2. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Treatment-Resistant Depression Market

• 22.1. Russia Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Treatment-Resistant Depression Market

• 23.1. North America Treatment-Resistant Depression Market Overview
• 23.2. North America Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Treatment-Resistant Depression Market

• 24.1. USA Treatment-Resistant Depression Market Overview
• 24.2. USA Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Treatment-Resistant Depression Market

• 25.1. Canada Treatment-Resistant Depression Market Overview
• 25.2. Canada Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Treatment-Resistant Depression Market

• 26.1. South America Treatment-Resistant Depression Market Overview
• 26.2. South America Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Treatment-Resistant Depression Market

• 27.1. Brazil Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Treatment-Resistant Depression Market

• 28.1. Middle East Treatment-Resistant Depression Market Overview
• 28.2. Middle East Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Treatment-Resistant Depression Market

• 29.1. Africa Treatment-Resistant Depression Market Overview
• 29.2. Africa Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Treatment-Resistant Depression Market Competitive Landscape And Company Profiles

• 30.1. Treatment-Resistant Depression Market Competitive Landscape
• 30.2. Treatment-Resistant Depression Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline (GSK) plc. Overview, Products and Services, Strategy and Financial Analysis

31. Treatment-Resistant Depression Market Other Major And Innovative Companies

• 31.1. Hikma Pharmaceuticals plc
• 31.2. Neurocrine Biosciences Inc.
• 31.3. Relmada Therapeutics Inc.
• 31.4. Neuronetics Inc.
• 31.5. COMPASS Pathways
• 31.6. Lykos Therapeutics
• 31.7. Reviva Pharmaceuticals
• 31.8. Celon Pharma SA
• 31.9. BrainsWay Ltd.
• 31.10. Magstim Company Limited
• 31.11. MindMed
• 31.12. Alto Neuroscience
• 31.13. Sage Therapeutics Inc.
• 31.14. MindBio Therapeutics Ltd.
• 31.15. Reunion Neuroscience

32. Global Treatment-Resistant Depression Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Treatment-Resistant Depression Market

34. Recent Developments In The Treatment-Resistant Depression Market

35. Treatment-Resistant Depression Market High Potential Countries, Segments and Strategies

• 35.1 Treatment-Resistant Depression Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Treatment-Resistant Depression Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Treatment-Resistant Depression Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34998_Treatment_Resistant_Depression_GMR_2025

관련자료